Fragile X Syndrome: all 115 studies

Page 1 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X SyndromeNot yet recruitingNCT07930520Phase 2
• Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious AvoidanceNot yet recruitingNCT07898592Not applicable
• Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X SyndromeRecruitingNCT07654114Phase 2
• Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal DisordersRecruitingNCT07493096
• A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADSNot yet recruitingNCT07439510Phase 2/3
• The Neurocognitive Bases of Trust in Intellectual DisabilityRecruitingNCT07434037
• Inhibition of Aggressive Behavior in Participants With Fragile X SyndromeNot yet recruitingNCT07328529Phase 2
• Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)RecruitingNCT07209462Phase 2
• Optical Imaging in X-linked Disorders.RecruitingNCT06868979Not applicable
• Physical Activity and Community EmPOWERment ProjectRecruitingNCT06740162Not applicable
• Group CBT in Adolescents With Fragile X Syndrome and in Adolescents With Autism Spectrum DisorderRecruitingNCT06677866Not applicable
• Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- InfantRecruitingNCT06560242Not applicable
• Optical Imaging as a Tool for Monitoring Brain Function in Fragile X SyndromeRecruitingNCT06293027
• Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X SyndromeRecruitingNCT06279858Not applicable
• Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X SyndromeRecruitingNCT06261502Phase 2
• Effect of CBD on the BrainNot yet recruitingNCT06261450Phase 2
• Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental DisordersRecruitingNCT06227780Not applicable
• Development of Non-Invasive Prenatal Diagnosis for Single Gene DisordersRecruitingNCT06147414
• Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental DisordersRecruitingNCT06081348Phase 2
• Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool AgeRecruitingNCT05957549Not applicable
• Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual DisabilitiesEnrolling by invitationNCT05301361Phase 1
• Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal CohortRecruitingNCT05295277
• Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or ObesityRecruitingNCT04768803
• Parent and Infant Inter(X)Action Intervention (PIXI)Enrolling by invitationNCT03836300Not applicable
• The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeRecruitingNCT00768820Phase 4
• Study of SPG601 in Adult Men With Fragile X SyndromeCompletedNCT06413537Phase 2Results posted
• Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)CompletedNCT06334419Phase 2Results posted
• ERG/5-HTP in Fragile X Syndrome (FXS)CompletedNCT05030129Phase 2Results posted
• A Study of OV101 in Individuals With Fragile X SyndromeCompletedNCT03697161Phase 2Results posted
• Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)CompletedNCT03614663Phase 2/3Results posted
• A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X SyndromeCompletedNCT03569631Phase 2Results posted
• Neurophysiological and Acute Pharmacological Studies in FXS PatientsCompletedNCT02998151Early Phase 1Results posted
• AFQ056 for Language Learning in Children With FXSCompletedNCT02920892Phase 2Results posted
• Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X SyndromeCompletedNCT02642653Phase 4Results posted
• Decisional Capacity and Informed Consent in Fragile X SyndromeCompletedNCT02465931Not applicableResults posted
• Ganaxolone Treatment in Children With Fragile X SyndromeCompletedNCT01725152Phase 2Results posted
• Trial of Sertraline to Treat Children With Fragile X SyndromeCompletedNCT01474746Phase 2Results posted
• Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)TerminatedNCT01433354Phase 2/3Results posted
• Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X SyndromeCompletedNCT01357239Phase 2Results posted
• Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X SyndromeTerminatedNCT01348087Phase 2Results posted
• Acamprosate in Youth With Fragile X SyndromeCompletedNCT01300923Phase 2Results posted
• Double-blind Placebo Controlled Study of Oxytocin in Fragile X SyndromeCompletedNCT01254045Phase 2Results posted
• Randomized Controlled Study of Donepezil in Fragile X SyndromeCompletedNCT01120626Phase 2Results posted
• Trial of Minocycline to Treat Children With Fragile X SyndromeCompletedNCT01053156Not applicableResults posted
• Riluzole in Fragile X SyndromeCompletedNCT00895752Phase 4Results posted
• Add-on Pilot Trial of Minocycline to Treat Fragile X SyndromeCompletedNCT00858689Not applicableResults posted
• Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X SyndromeCompletedNCT00788073Phase 2Results posted
• A Prospective Open-label Study of Aripiprazole in Fragile X SyndromeCompletedNCT00420459Phase 2Results posted
• Neural Biomarkers in Fragile X SyndromeCompletedNCT06957054
• CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food InteractionCompletedNCT06480968Phase 1
• Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)Active, not recruitingNCT06139172Not applicable
• Speech-in-noise Perception in Autism and Fragile XCompletedNCT06088589Not applicable
• An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X SyndromeSuspendedNCT05832255Phase 2
• Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug ChallengeActive, not recruitingNCT05418049Phase 2
• An Open-Label Extension Study of BPN14770 in Subjects With Fragile X SyndromeActive, not recruitingNCT05367960Phase 3
• A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromeCompletedNCT05358886Phase 3
• A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X SyndromeCompletedNCT05163808Phase 2/3
• Metformin in Children With Fragile X SyndromeCompletedNCT05120505Phase 4
• Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X SyndromeCompletedNCT04977986Phase 3
• Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X SyndromeStatus unknownNCT04869930
• Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40WithdrawnNCT04823052Phase 2
• NIPD on cffDNA for Triplet Repeat DiseasesStatus unknownNCT04698551
• Cooperative Parent Mediated Therapy in Children With Fragile X Syndrome and Williams SyndromeStatus unknownNCT04610424Not applicable
• Novel Clinical Target in Fragile X SyndromeWithdrawnNCT04314856Phase 1
• Neuroimaging GABA Physiology in Fragile X SyndromeTerminatedNCT04308954Phase 1
• Metformin in Patients With Fragile XStatus unknownNCT04141163Phase 1/2
• A Non-Interventional Pilot Study to Explore the Role of Gut Flora in AutismWithdrawnNCT04100863
• A Trial of Metformin in Individuals With Fragile X Syndrome (Met)CompletedNCT03862950Phase 2
• Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXSActive, not recruitingNCT03802799Phase 2/3
• Metformin in Children and Adults With Fragile X SyndromeCompletedNCT03722290Phase 2
• Early Check: Expanded Screening in NewbornsActive, not recruitingNCT03655223
• Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)CompletedNCT03624556Not applicable
• Treatment of Disruptive Behaviors in Fragile X SyndromeCompletedNCT03510156Not applicable
• A Trial of Metformin in Individuals With Fragile X SyndromeCompletedNCT03479476Phase 2/3
• An Initial Study of AZD7325 in Adults With Fragile X SyndromeCompletedNCT03140813Phase 1
• Single Dose Pharmacokinetic (PK) StudyCompletedNCT03109756Phase 1
• NIPD on CFTC for Triplet Repeat DiseasesCompletedNCT03087526Not applicable
• Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X SyndromeCompletedNCT02942498Phase 3
• Pediatric Patients With Metabolic or Other Genetic DisordersCompletedNCT02769949
• Cognitive Training for Fragile X SyndromeCompletedNCT02747394Not applicable
• Glutaminergic Transmission in Autism : Molecular Imaging ExplorationCompletedNCT02719951Phase 1
• Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X SyndromeCompletedNCT02680379Phase 2
• Effects of Social Gaze Training on Brain and Behavior in Fragile X SyndromeCompletedNCT02616796Phase 1/2
• Parents Resources for Decreasing the Incidence of Change Triggered Temper OutburstsCompletedNCT02567357Phase 1
• A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X SyndromeCompletedNCT02126995Phase 2
• Study of Acamprosate in Fragile x SyndromeCompletedNCT01911455Phase 1
• A Safety Study of NNZ-2566 in Patients With Fragile X SyndromeCompletedNCT01894958Phase 2
• "Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX)CompletedNCT01855971Phase 2
• A Study of RO4917523 in Pediatric Patients With Fragile X SyndromeCompletedNCT01750957Phase 2
• EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related OutcomesTerminatedNCT01711606
• Validation of Saliva in the Esoterix Genetic Laboratories Fragile X AssayStatus unknownNCT01616589
• An Open Label Extension Study in Subjects With Fragile X SyndromeTerminatedNCT01555333Phase 3
• A Study of RO4917523 in Patients With Fragile X SyndromeCompletedNCT01517698Phase 2
• Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)CompletedNCT01482143Phase 1
• Brain Connectivity in Neurodevelopmental Disorders in Response to TreatmentCompletedNCT01364818
• Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X SyndromeCompletedNCT01329770Phase 2
• A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X SyndromeSuspendedNCT01325740Phase 2
• Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X SyndromeCompletedNCT01325220Phase 3
• Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X SyndromeCompletedNCT01282268Phase 3
• Safety and Efficacy of AFQ056 in Adult Patients With Fragile X SyndromeCompletedNCT01253629Phase 2

← Fragile X Syndrome overview